表柔比星、顺铂及5-氟尿嘧啶持续静脉输注化疗用于晚期涎腺腺样囊性癌
Epirubicin, cisplatin and protracted venous infusion 5-Fluorouracil chemotherapy for advanced salivary adenoid cystic carcinoma.
作者信息
Ross P J, Teoh E M, A'hern R P, Rhys-Evans P H, Harrington K J, Nutting C M, Gore M E
机构信息
The Head and Neck Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK.
出版信息
Clin Oncol (R Coll Radiol). 2009 May;21(4):311-4. doi: 10.1016/j.clon.2008.12.009. Epub 2009 Feb 7.
AIMS
Adenoid cystic carcinoma (ACC) is a rare tumour that usually arises in the salivary glands. Initial management is surgery often combined with adjuvant radiotherapy. Chemotherapy is reserved for treatment of symptomatic recurrence. We evaluated the combination of epirubicin, cisplatin and protracted venous infusion 5-fluorouracil (ECF) in the management of ACC.
MATERIALS AND METHODS
Patients referred for treatment of advanced, symptomatic ACC were considered. The drugs given were epirubicin 50 mg/m(2) 3-weekly, cisplatin 60 mg/m(2) 3-weekly and protracted venous infusion 5-fluorouracil 200 mg/m(2)/day.
RESULTS
Eight patients (median age 46 years) received a median of five cycles of chemotherapy. All patients had had previous surgery, seven had had previous radiotherapy and one had had previous chemotherapy. One patient showed a partial response (duration 34 months) and five showed stable disease (median duration 13.6 months [6.8-15.9+ months]). Median survival was 27 months (3.5-62.3 months).
CONCLUSIONS
The activity of ECF in ACC of the head and neck seems to be similar to the combination of cisplatin and 5-fluorouracil and single-agent epirubicin.
目的
腺样囊性癌（ACC）是一种罕见肿瘤，通常发生于涎腺。初始治疗为手术，常联合辅助放疗。化疗则用于有症状复发的治疗。我们评估了表柔比星、顺铂和持续静脉输注5-氟尿嘧啶（ECF）联合方案在ACC治疗中的效果。
材料与方法
纳入因晚期有症状ACC前来治疗的患者。给予的药物为表柔比星50mg/m²，每3周1次；顺铂60mg/m²，每3周1次；持续静脉输注5-氟尿嘧啶200mg/m²/天。
结果
8例患者（中位年龄46岁）接受了中位5个周期的化疗。所有患者均曾接受过手术，7例曾接受过放疗，1例曾接受过化疗。1例患者出现部分缓解（持续时间34个月），5例病情稳定（中位持续时间为13.6个月[6.8 - 15.9 +个月]）。中位生存期为27个月（3.5 - 62.3个月）。
结论
ECF对头颈部ACC的疗效似乎与顺铂和5-氟尿嘧啶联合以及表柔比星单药治疗相似。
Zotero 插件